Dr Isabel Marchbank
- Address: Institute of Cellular Medicine
3rd Floor William Leach Building
I am a viral immunologist that has migrated into the area of complement biology.
Roles and responsibilities
I am responsible for general lab management and safety.
Supervision of undergraduates and masters students within the lab.
Progressing my own research within the group.
June 2006 Doctor of Philosophy (Viral imunology) University of Birmingham.
June 1999 BSc (Hons) 2:1 Biochemistry University of Liverpool.
Oct 2006-Jan 2010 E grade technician at Newcastle university.
Working on multiple projects including tissue culture, protein work, cloning and in vivo
Jan 2004-Oct 2006 Post doctoral researcher Cardiff university.
Investigating the interaction between NK calls and B cells in the productive lytic cycle.
Improving the in vivo pharmacokenetics of a mini-FH therapeutic construct.
The complement regulator factor H (FH) has been shown to be of interest as a bological therapeutic. This remains the case in vitro when the large regulatory domain is removed from the middle of the protein. This new mini-FH functions well and has had an affect in vivo but this is only transient.
Sucessful targeting and enhancment of serum half-life could mean that this therapeutic agent could be used in a broard spectrum of clinical situations.
We aim to increase the serum half-life by inclusion of glycosaminoglycan targeting polypeptides or inclusion of an Fc (n) polypeptide.
Once these altered mini-FH are produced we will test if serum half-life has been altered and the effect, if any, on FH function.
- Goodship THJ, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ. Factor H autoantibodies in membranoproliferative glomerulonephritis. Molecular Immunology 2012, 52(3-4), 200-206.
- Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L, Ward R, Plant N, Nailescu C, Goodship TH, Marchbank KJ. Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?. Clinical Journal of the American Society of Nephrology 2012, 7(3), 417-426.
- Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship THJ, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115(2), 379-387.
- Dhillon B, Wright AF, Tufail A, Pappworth I, Hayward C, Moore I, Strain L, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Armbrecht AM, Laude A, Deary IJ, Staniforth SJ, Holmes LV, Goodship THJ, Marchbank KJ. Complement Factor H Autoantibodies and Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science 2010, 51(11), 5858-5863.
- Pappworth IY, Denton M, Kavanagh D, Moore I, Strain L, Barlow PN, Herbert AP, Schmidt CQ. Factor H autoantibodies are associated with MPGN. In: Molecular Immunology: 23rd International National Complement Workshop. 2010, New York, USA: Pergamon.
- Kavanagh D, Pappworth IY, Roversi P, Tapson JS, Moore I, Strain L, Lea S, Goodship THJ, Marchbank KJ. Factor I autoantibodies are associated with atypical haemolytic uraemic syndrome. In: Molecular Immunology: 23rd International National Complement Workshop. 2010, New York, USA: Pergamon.
- Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship THJ, Rees L. Successful Renal Transplantation in Factor H Autoantibody Associated HUS with CFHR1 and 3 Deficiency and CFH Variant G2850T. American Journal of Transplantation 2010, 10(1), 168-172.
- Pappworth IY, Cruickshank MN, Hayes C, Knight AM, Ulgiati D, Marchbank KJ. The role of complement in the formation of B regulatory cells. In: Immunology: Annual Congress of the British Society for Immunology. 2010, Liverpool, UK: Wiley-Blackwell Publishing, Inc.
- Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Molecular Immunology 2009, 46(10), 2002-2013.
- Pappworth IY, Kulik L, Haluszczak C, Reuter JW, Holers VM, Marchbank KJ. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Molecular Immunology 2009, 46(6), 1042-1049.
- Pappworth IY, Marchbank KJ. Normal B cell ontogeny in mice expressing human complement receptor type 1 under the control of a lambda light chain promoter enhancer. In: 11th European Meeting on Complement in Human Disease. 2007, Cardiff, Wales: Molecular Immunology, Pergamon.